Revolutionizing Antibody Discovery: How neoSwitch & Opentrons Flex Unlock Scalable Automation

Antibody discovery no longer requires million-dollar investments in outsourced services. With neoSwitch and Opentrons Flex, biotech startups, biopharma companies, and research labs can access an end-to-end, automated workflow that makes high-throughput screening more efficient, scalable, and cost-effective than ever before.

Join us to explore how this turnkey solution empowers teams to accelerate discovery in-house, ensuring consistency and control over timelines and costs. Learn how automation is being democratized—making cutting-edge antibody discovery accessible to labs of all sizes.